NCT00061750View on ClinicalTrials.gov

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

PHASE3CompletedINTERVENTIONAL
Enrollment

595

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

November 30, 2004

Conditions
Beta-Thalassemia
Interventions
DRUG

ICL670

DRUG

deferoxamine

Trial Locations (7)

10021

Weill Medical College of Cornell University, New York

94609

Children's Hospital Oakland, Oakland

90027-6062

Children's Hospital of Los Angeles, Los Angeles

94305-5208

Stanford Hospital, Stanford

60614-3394

Children's Memorial Hospital, Chicago

02115

Children's Hospital Boston, Boston

19104-4318

Children's Hospital of Philadelphia, Philadelphia

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY